Cortexyme Inc CRTX:NASDAQ

Last Price$42.49Cboe Real-Time Last Sale as of 3:03PM ET 6/03/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.74(3.93%)
Bid (Size)$42.33 (5)
Ask (Size)$42.77 (100)
Day Low / High$42.26 - 45.08
Volume162.6 K
 

View Biotechnology IndustryPeer Comparison as of 06/03/2020

 

Cortexyme Inc ( NASDAQ )

Price: $42.49
Change: -1.74 (3.93%)
Volume: 162.6 K
3:03PM ET 6/03/2020
 
 

Veracyte Inc ( NASDAQ )

Price: $26.15
Change: +0.14 (0.54%)
Volume: 183.9 K
3:19PM ET 6/03/2020
 
 

Karyopharm Therapeutics Inc ( NASDAQ )

Price: $17.57
Change: -0.51 (2.82%)
Volume: 1.2 M
3:16PM ET 6/03/2020
 
 

Arvinas Inc ( NASDAQ )

Price: $33.32
Change: +0.69 (2.11%)
Volume: 494.8 K
3:20PM ET 6/03/2020
 
 

Cytokinetics Inc ( NASDAQ )

Price: $20.69
Change: -0.42 (1.99%)
Volume: 248.1 K
3:19PM ET 6/03/2020
 

Read more news Recent News

Analyst Actions: Jefferies Starts Cortexyme at Buy With $59 Price Target
9:44AM ET 6/02/2020 MT Newswires

Cortexyme (CRTX) has an average analyst rating of hold, with an average price target of $45. Price: 45.49, Change: +1.05, Percent Change: +2.36 ...

Insider Trends: Insider Buying Added to with Purchase of Cornerstone Therapeutics Shares
6:43PM ET 5/19/2020 MT Newswires

On May 15, 2020, Director, David Lamond, reported a purchase of 44,648 shares in Cornerstone Therapeutics (CRTX) for $2,471,251. Lamond, following the...

--Analyst Actions: Canaccord Genuity Lifts Cortexyme's Price Target to $70 From $42, Keeps Buy Rating
12:12PM ET 5/13/2020 MT Newswires

Price: 48.66, Change: +2.88, Percent Change: +6.29 ...

Cortexyme Q1 Loss Narrows But Misses Street View
5:38AM ET 5/13/2020 MT Newswires

Cortexyme (CRTX) reported Tuesday Q1 net loss of $0.61 per share, narrower than last year's loss of $1.61 per share but still behind the Street's average...

View all Commentary and Analysis

Insider Weekends: Moderna Executives Go On A Selling Spree
11:20AM ET 5/25/2020 Seeking Alpha

Medtronic's Patent Challenge, And Other News: The Good, Bad And Ugly Of Biopharma
4:57PM ET 3/19/2020 Seeking Alpha

An Uber Exciting Week (Stocks To Watch Podcast)
7:30AM ET 11/03/2019 Seeking Alpha

Stocks To Watch: An Uber Exciting Week
8:42AM ET 11/02/2019 Seeking Alpha

Company Profile

Business DescriptionCortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA. View company web site for more details
Address269 East Grand Ave
South San Francisco, California 94080
Phone+1.650.910.5717
Number of Employees19
Recent SEC Filing06/01/2020S-3ASR
Chairman, President & Chief Executive OfficerCasey Crawford Lynch
CFO, Treasurer & Principal Accounting OfficerChristopher P. Lowe
Chief Scientific Officer & DirectorStephen S. Dominy
Executive Vice President-Research & DevelopmentLeslie J. Holsinger

Company Highlights

Price Open$43.97
Previous Close$44.23
52 Week Range$19.35 - 73.84
Market Capitalization$1.2 B
Shares Outstanding29.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/14/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.01
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-32.48%

Analyst Ratings as of 05/29/2020

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset